- Home
- LRE vs PSNL Comparison
LRE vs PSNL Comparison
Compare LRE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- PSNL
- Stock Information
- Founded
- LRE 2001
- PSNL 2011
- Country
- LRE Japan
- PSNL United States
- Employees
- LRE N/A
- PSNL N/A
- Industry
- LRE
- PSNL Medical Specialities
- Sector
- LRE
- PSNL Health Care
- Exchange
- LRE Nasdaq
- PSNL Nasdaq
- Market Cap
- LRE 17.6M
- PSNL 576.8M
- IPO Year
- LRE 2023
- PSNL 2019
- Fundamental
- Price
- LRE N/A
- PSNL $7.32
- Analyst Decision
- LRE
- PSNL Strong Buy
- Analyst Count
- LRE 0
- PSNL 5
- Target Price
- LRE N/A
- PSNL $8.00
- AVG Volume (30 Days)
- LRE 14.8K
- PSNL 1.7M
- Earning Date
- LRE 01-01-0001
- PSNL 08-06-2025
- Dividend Yield
- LRE N/A
- PSNL N/A
- EPS Growth
- LRE N/A
- PSNL N/A
- EPS
- LRE N/A
- PSNL N/A
- Revenue
- LRE $110,330,328.00
- PSNL $85,694,000.00
- Revenue This Year
- LRE N/A
- PSNL $0.45
- Revenue Next Year
- LRE N/A
- PSNL $25.75
- P/E Ratio
- LRE N/A
- PSNL N/A
- Revenue Growth
- LRE 8.82
- PSNL 15.57
- 52 Week Low
- LRE $1.10
- PSNL $1.19
- 52 Week High
- LRE $2.49
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- LRE 57.65
- PSNL 77.17
- Support Level
- LRE $1.71
- PSNL $6.27
- Resistance Level
- LRE $2.11
- PSNL $7.03
- Average True Range (ATR)
- LRE 0.12
- PSNL 0.52
- MACD
- LRE -0.01
- PSNL 0.08
- Stochastic Oscillator
- LRE 34.69
- PSNL 83.65
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.